

Implementing WHA78.10 (2025): From evidence to action - strengthening the impact of WHO norms and standards

22 July 2026

Member State Information Session

Agenda



Session objectives

- Recall the key provisions of WHA Resolution 78.10
- Outline the development process and timeline for the consultative process of the Global Framework and Action Plan
- Provide guidance to Member States on how to share their inputs to the Framework and Action Plan
- Collect Member States' perspectives, comments and questions to inform the development process and first drafts

World Health Assembly Resolution 78.10



The mandate: WHA78.10

In May 2025, the 78th World Health Assembly adopted Resolution 78.10 on

“Strengthening national capacities in evidence-based decision-making for the uptake and impact of norms and standards”



Supports Member States in **translating evidence and WHO norms and standards** into effective policies, programmes and improved health outcomes.



Calls for **stronger national systems and capacities** to generate, adapt, implement and use evidence in decision-making, including the contextualization of WHO guidance.

Strengthening national capacities in evidence-based decision-making for the uptake and impact of norms and standards

The Seventy-eighth World Health Assembly,

Having considered the report by the Director-General;¹

Recalling the collective commitment to achieve universal health coverage and the role of evidence, knowledge and innovation in promoting quality of care, improving financial protection and driving positive outcomes;

Recognizing WHO's unique status as a science- and evidence-based organization and its normative leadership, as outlined in its Constitution and in the Fourteenth General Programme of Work, 2025–2028, with its renewed focus on country-level impact including through timely delivery, expanded access to and uptake of WHO's normative, technical and data products;

Recalling the experiences encountered during the pandemic of coronavirus disease (COVID-19) and the need for robust and timely clinical and public health guidance that is relevant to context and responsive to local needs and equity considerations;

Recognizing scientific evidence as an important basis for the development of clinical and public health guidance; and recognizing also the value of science and high-quality evidence in ensuring that complex information is synthesized and available in accessible formats for end-users to guide practice and improve health outcomes;

Concerned that there are significant gaps, including inadequate resources, in the capacity of countries to produce and use relevant local and global evidence in developing new clinical and public health guidelines or in adapting existing guidelines with proper feedback systems to measure the cost-effectiveness and quality of clinical care, public health guidance and policy and their impact on population health and well-being;

Recalling the Constitution of the World Health Organization, resolution WHA75.8 (2022) on strengthening clinical trials to provide high-quality evidence on health interventions and to

The mandate: WHA78.10

The Seventy-eighth World Health Assembly [...]

requests the Director-General [...]



Seventy-eighth World Health Assembly

Agenda item 13.3

27 May 2025

WHA78.10

Strengthening national capacities in evidence-based decision-making for the uptake and impact of norms and standards

The Seventy-eighth World Health Assembly,

Having considered the report by the Director-General;¹

Recalling the collective commitment to achieve universal health coverage and the role of evidence, knowledge and innovation in promoting quality of care, improving financial protection and driving positive outcomes;

Recognizing WHO's unique status as a science- and evidence-based organization and its normative leadership, as outlined in its Constitution and in the Fourteenth General Programme of Work, 2025–2028, with its renewed focus on country-level impact including through timely delivery, expanded access to and uptake of WHO's normative, technical and data products;

Recalling the experiences encountered during the pandemic of coronavirus disease (COVID-19) and the need for robust and timely clinical and public health guidance that is relevant to context and responsive to local needs and equity considerations;

Recognizing scientific evidence as an important basis for the development of clinical and public health guidance; and recognizing also the value of science and high-quality evidence in ensuring that complex information is synthesized and available in accessible formats for end-users to guide practice and improve health outcomes;

Concerned that there are significant gaps, including inadequate resources, in the capacity of countries to produce and use relevant local and global evidence in developing new clinical and public health guidelines or in adapting existing guidelines with proper feedback systems to measure the cost-effectiveness and quality of clinical care, public health guidance and policy and their impact on population health and well-being;

Recalling the Constitution of the World Health Organization, resolution WHA75.8 (2022) on strengthening clinical trials to provide high-quality evidence on health interventions and to



*to develop, within existing resources, in close consultation with Member States and with inputs from relevant stakeholders, inline with the Framework of Engagement with Non-State Actors, as applicable, a **global framework on uptake and impact of norms and standards and a global plan of action for the implementation of the framework in 2027; [...]***




*to **report on progress made** in the implementation of this resolution to the Eightieth, Eighty-second and Eighty-fourth World Health Assemblies in 2027, 2029 and 2031.*

WHA78.10 (2005)

Requested documents by WHA78.10: general structure

The Framework defines the strategic direction; the Action Plan translates it into implementation



Global framework and plan of action: development process and timeline



WHO Secretariat

Development coordinated by

Science for Health Department

in close collaboration with
WHO Headquarters • Regional Offices • Country Offices



**Dr Tedros Adhanom
Ghebreyesus**

Director-General



Dr Sylvie Briand


Chief Scientist



Dr Meg Doherty

Director, Science for
Health

Co-developing the global framework and plan of action



Additional funding support is sought to ensure a comprehensive, inclusive, and rigorous development process.


Guiding principles



Country-led and
inclusive



Evidence-informed and
context-sensitive



Transparent and
iterative



Coordinated across
HQ, Regional &
Country Offices



Focused on
implementation
and impact




OUR GOAL: A practical, implementable Framework and Action Plan that
accelerate uptake, implementation and impact of WHO norms and standards

Your inputs to the framework and action plan



How Member States can engage

Through (virtual) global or regional consultations as well as request for written inputs, allowing for continuous refinement of the drafts



Regional Consultations

- Launch regional consultations through a high-level ministerial side event at the AFRO Regional Committee.
- Consultations may be conducted alongside [Regional Committee meetings](#) or as standalone events.
- WHO Secretariat is preparing a briefing note outlining key principles and guiding questions to support consultations.

**OBJECTIVES**

**Co-creation**
Engage Member States early through consultations

**Gather early input**
Collect perspectives on priorities, principles and key questions

**Inform**
Inform the development of the Global Framework and Action Plan

 REGIONAL COMMITTEE CONSULTATION CALENDAR	
Regional Committee for Africa (AFRO)	24 – 28 Aug 2026
Regional Committee for South-East Asia (SEARO)	7 – 10 Sep 2026
Regional Committee for the Americas (PAHO)	28 Sep – 2 Oct 2026
Regional Committee for the Eastern Mediterranean (EMRO)	13 – 15 Oct 2026
Regional Committee for the Western Pacific (WPRO)	19 – 23 Oct 2026
Regional Committee for Europe (EURO)	27 – 29 Oct 2026

Example questions to be discussed throughout the consultations

Relevance and priorities

Where do you see the greatest gaps between WHO guidance and actual implementation in your context?

What should be the top priorities or features of this global framework and action plan to ensure it is useful and actionable for your country?

Current practices

Where can WHO add the greatest value in strengthening the “norms-to-impact” pathway?

Existing systems

What systems or mechanisms exist in your country for evidence-to-policy translation (e.g., guideline adaptation, HTA, advisory bodies)?

Vision

What tangible changes would you expect to see at country level because of this framework over the next 10 years?

Questions

Reflections

Comments

Thank you

For any questions, concerns or additional comments, please contact:

Meg Doherty

Director, Science for Health Department

Science Division

World Health Organization

dohertym@who.int